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Abstract: Background: Whether the bone mineral density (BMD) T-score performs differently in
osteoporosis classification in women of different genetic profiling and race background remains
unclear. Methods: The genomic data in the Women’s Health Initiative study was analyzed (n = 2417).
The polygenic score (PGS) was calculated from 63 BMD-associated single nucleotide polymorphisms
(SNPs) for each participant. The World Health Organization0 s (WHO) definition of osteoporosis
(BMD T-score ≤ −2.5) was used to estimate the cumulative incidence of fracture. Results: T-score
classification significantly underestimated the risk of major osteoporotic fracture (MOF) in the WHI
study. An enormous underestimation was observed in African American women (POR: 0.52, 95%
CI: 0.30–0.83) and in women with low PGS (predicted/observed ratio [POR]: 0.43, 95% CI: 0.28–0.64).
Compared to Caucasian women, African American, African Indian, and Hispanic women respectively
had a 59%, 41%, and 55% lower hazard of MOF after the T-score was adjusted for. The results were
similar when used for any fractures. Conclusions: Our study suggested the BMD T-score performance
varies significantly by race in postmenopausal women.
Keywords: polygenic score (PGS); bone mineral density (BMD); single nucleotide polymorphism
(SNP)

1. Introduction
Osteoporosis is a common, progressive systemic skeletal disease characterized by low bone
mass and deteriorated bone tissue, resulting in an increase in bone fragility and susceptibility to
fracture [1]. Osteoporosis-associated fractures often cause a significant increase in morbidity, mortality,
and accompanying social and economic costs [2]. By estimation, about 50% of postmenopausal
Caucasian women and 20% of Caucasian men in the US will suffer at least one fragility fracture after
the age of 50 [3]. With life expectancy increasing universally, osteoporosis and fracture will become an
ever-growing health problem worldwide [4].
Osteoporosis is a silent disease because bone loss occurs or bone tissue deteriorates without any
symptoms [4]. Patients often are not aware that they have osteoporosis until a fracture occurs. Thus,
correctly diagnosing osteoporosis and identifying individuals who will sustain osteoporotic fracture
is critical for the prevention of devastating fracture outcomes in the aging population. As BMD is
the single strongest predictor of primary osteoporotic fracture [5], clinical osteoporosis diagnosis is
based on BMD measurements from dual-energy x-ray absorptiometry (DEXA) assessment [6]. The
J. Clin. Med. 2020, 9, 499; doi:10.3390/jcm9020499
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World Health Organization established commonly accepted definitions of osteoporosis as a femur
neck BMD that lies ≥2.5 standard deviations below (T-score ≤ −2.5) the mean value for young, healthy
women [7]. This definition becomes the WHO international reference standard for osteoporosis
diagnosis. However, the major limitation of this WHO reference standard is its low sensitivity; most
fractures occur in individuals with a femur neck BMD T-score > −2.5. In addition, because many other
risk factors, including age, female gender, and previous fracture, are associated with fracture risk
independently of BMD, several predictive models have been developed to estimate fracture risk from
these established risk factors. The Fracture Risk Assessment Tool (FRAX) is the most commonly used
fracture risk assessment tool in the US [8]. Although FRAX improves fracture prediction over the BMD
T-score method alone, the predictive performance of both FRAX and WHO T-score method varies in
different population cohorts [8,9] and with different conditions [10,11].
The original FRAX was developed from nine large cohorts and then validated in 11 independent
cohorts across the world [1]. The US FRAX was calibrated from the data of the Rochester Epidemiology
Project [12], composed predominantly of Caucasians [13]. Further, the T-score was initially proposed
only for postmenopausal Caucasian women [14,15]. Although both FRAX and T-score were adjusted
subsequently for race and ethnicity, the methodology for the adjustment was not empirically based,
thus rendering their performance for fracture prediction unreliable in minorities. In addition, neither
FRAX nor T-score takes account of genetic components even though research has shown that hereditary
factors are determinants of bone structure and are strongly associate with bone mass decrease, bone
deterioration, and fragility fractures. With the development of advanced genomic technologies,
numerous genetic loci related to fracture and BMD have been discovered in major genome-wide
association studies (GWASs) and genome-wide meta-analyses. Both of these factors provide a unique
opportunity to examine the performance of existing clinical fracture prediction approaches in groups
with different genomic profiling.
Our previous study has examined the performance of FRAX in postmenopausal women by
race and polygenic score, computed from fracture-associated SNPs discovered in the largest GWAS
meta-analysis (under review). The T-score method (T-score ≤ −2.5) is the WHO international reference
standard for osteoporosis diagnosis and has been endorsed by numerous professional societies,
including the International Society of Clinical Densitometry (ISCD) [16], and widely used in clinical
practice for osteoporosis diagnosis. However, the performance of the T-score method for osteoporosis
classification in the U.S. minorities was rarely studied, and the T-score performance in osteoporosis
classification with different genetic profiling has never been reported in the literature. Thus, this study
aimed first to evaluate whether T-score performs differently in osteoporosis classification with different
polygenic risk scores, and second to assess T-score performance in osteoporosis diagnosis by race in
women. We also examined the extent to which the interaction of race and polygene scores impacts the
T-score performance in osteoporosis classification and fracture prediction.
2. Experimental Section
2.1. Data Source
The Women’s Health Initiative (WHI) study is a nationwide longitudinal study to examine the
health of postmenopausal women aged 50–79 years old who have no severe medical conditions at
baseline [17]. Between 1993 and 1998, the WHI enrolled 161,809 women aged 50 to 79 years old at
40 clinical centers nationwide. The details of WHI recruitment and follow-up procedures have been
described elsewhere [17]. Briefly, eligible women were enrolled in one or more randomized Clinical
Trials (CT) or to an Observational Study (OS). Participants were followed up on by mail or telephone
semiannually in CT and with questionnaires annually in the OS. The Institutional Review Boards at
each participating institution approved the study protocols and participant consent forms [17].
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2.2. Participants
The data used for the present study were de-identified and were acquired through the database
of Genotype and Phenotype (dbGap) (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?
study_id=phs000200.v12.p3) with the approval of the institutional review board at the University of
Nevada, Las Vegas. The data included in this analysis were merged from four WHI sub-studies, WHI
Genomics and Randomized Trials Network (GARNET), National Heart Lung, and Blood Institute
(NHLBI), Population Architecture using Genomics and Epidemiology (PAGE), and Women’s Health
Initiative Memory Study (WHIMS). On baseline questionnaires, participants provided information
on age, race/ethnicity, smoking, physical activity, and supplement use. The included subjects were
genotyped using either the Affymetrix 6.0 array set (Affymetrix, Santa Clara, CA, USA) or the
Illumina (Illumina, San Diego, CA, USA) platform. Participants who reported taking any medication
known to influence osteoporosis, including corticosteroid bisphosphonates, calcitonin, parathyroid
hormone, selective estrogen receptor modulators, luteinizing hormone-releasing hormone agents, and
somatostatin agents, as well as participants who did not have BMD measurements were excluded from
the analytic sample. In total, there were 2417 eligible participants from multiple ethnic backgrounds,
with genotype data and adjudicated fracture outcomes available.
2.3. BMD Measurements
BMD was measured for women using dual-energy X-ray absorptiometry (QDR 2000 or 2000+, or
4500 W; Hologic Inc, Bedford, MA, USA) at three participating US clinical centers (Birmingham, AL;
Pittsburgh, PA; and Tucson/Phoenix, AZ). Certified technicians using standard protocols measured
BMD of the total hip, lumbar spine (L2–L4), and total body. Baseline BMD measurements were
employed to classify participants in order to determine if they have osteoporosis at baseline in this
study. Standard quality assurance protocols for positioning and analysis, routine hip and spine
phantoms, and review of a randomly selected sample were employed. Changes of hardware and
software were centralized and calibrated, and calibration phantoms across instruments and clinical
sites were in close agreement, with inter-scanner variability <1.5% for the spine, <4.8% for the hip,
and <1.7% for linearity [18]. BMD T-scores were calculated for each individual by using the young
adult, normal Caucasian women reference databases. Osteoporosis was defined as a BMD that lies 2.5
standard deviations or less below the average value for young, healthy women [19].
2.4. Outcomes: Incident Fractures
In this study, any fractures were defined as all fractures except those of fingers, toes, ribs, sternum
(or chest), skull (or face), and cervical vertebrae. Major osteoporotic fracture (MOF) was defined
as a composite of hip, humerus, forearm, and clinical vertebral fractures. The study participants
were followed for 19 years, from the inception of WHI initial study to the end of the WHI extension
study II, to ensure a sufficiently long follow-up duration to capture enough events. The follow-up
period was computed from the date of the enrollment (OS) or randomization (CT) to the time of the
first fracture or the time of death. Self-reported fracture outcomes were identified annually in OS
and semiannually in CT by questionnaires. All fractures in the CT and hip fractures in the OS were
adjudicated by using radiology reports. Hip fractures were adjudicated centrally or locally using the
same criteria. The agreement between central and local adjudication was 96% for hip fractures [20].
Other types of fractures were adjudicated locally at the clinical centers which were not designed for
BMD measurements in the WHI study [17].
2.5. Genotyping
Blood samples were genotyped using genomic DNA for WHI participants. Genomic data of
WHI were acquired through dbGap. Genotype imputation was conducted at the Sanger Imputation
Server to impute variants that were missing, un-typed, or poorly captured in the original data. The
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Haplotype Reference Consortium (HRC) reference panel and Positional Burrows-Wheeler Transform
(PBWT) imputation algorithm were employed for genotype imputation. All 63 fracture-associated
SNPs reported by Estrada et al. [21] were successfully imputed. The imputation quality was high, with
R2 = 0.99.
2.6. Polygenic Score
Genetic risk for decreased BMD was quantified using a standardized metric described in detail
by Estrada et al. [21]. Briefly, this metric allows the composite assessment of genetic risk for complex
traits by summarizing the genetic predisposition. Based on 63 femoral neck BMD-associated SNPs
discovered in the largest genome-wide meta-analysis [21], the polygenic score was computed as PGS =
sum (xi × bi ); where xi are individual’s genotype (0, 1, 2) for SNP i, and bi are the effect size of this SNP.
Linkage disequilibrium (LD) pruning was executed in advance to remove possible LD that existed
between SNPs. None of the 63 SNPs were deleted after pruning. To demonstrate if the performance of
the WHO international reference standard for osteoporosis diagnosis varied by PGS, eligible WHI
participants were divided into three PGS groups using distribution of 25%, 50%, and 25%.
2.7. Statistical Analysis
Demographic and baseline clinical characteristics are presented as mean ± SD for continuous
variables or frequencies (%) for categorical variables. Differences between the individuals with and
without a fracture were examined by using Student’s t-test for continuous variables and by using
chi-square tests or Fisher’s exact test (when numbers were small) for categorical variables, respectively.
PGS in different races was examined by using ANOVA. The observed cumulative incidence of fracture
from the start of WHI to the end of WHI extended II was assessed by race and PGS groups. The
cumulative incidence function (CIF) was applied to derive the observed fracture probability for MOF
and any fracture with competing mortality risk accounted for. The ratio between T-score predicted
fracture incidence and observed fracture incidence (POR), with the corresponding 95% CI, was
calculated for each subgroup.
To assess the performance of the T-score method in classifying osteoporosis in different subgroups,
the false-positive rate, and the false-negative rate was calculated for each PGS and race group.
Multivariate Cox Proportional Hazard Model was employed to assess the effect of PGS and race on the
outcome of MOF or any fracture within 19 years, with baseline T-score controlled for. To further assess
whether the effect of PGS and race on the outcome of MOF or any fracture are independent of other
common risk factors of osteoporosis, separate multivariate Cox Proportional Hazard Models were
conducted with baseline T-score, age, body mass index (BMI), and previous fracture controlled for. The
T-score diagnosis was treated as a binary categorical variable in the Cox Proportional Hazard Model.
Considering that the PGS used in the present study was calculated based on femoral neck BMD-related
SNPs, we also assessed whether the predictive value of PGS for hip fracture would be different from
other types of fracture. A multinomial logistic regression with three outcomes (hip fracture, non-hip
fracture, non-fracture) was performed.
A series of sensitivity analyses were also conducted, with the first one was conducted on a small
sample (N = 1775) in which participants who had previous fractures were excluded. To be comparable
with FRAX, which assess the 10-year probability of MOF, the POR between predicted fracture incidence
and observed incidence of MOF and any fracture in 10 years were also assessed, along with the
false-positive rate and false-negative rate for MOF and any fracture classification in different PGS and
race groups with 10-year follow up. A subgroup analysis was conducted to assess whether PGS would
predict fracture differently in osteopenia patients, and participants with normal BMD at baseline.
Statistical analyses were performed using the SAS 9.4 (SAS Institute, Inc., Cary, NC, USA).
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3. Results
3.1. Baseline Characteristics
The study included a total of 2417 women for analysis. During the 19-year follow-up period,
634 (26.23%) women died, and 289 (11.96%) women sustained at least one fracture at any skeletal site
during the follow-up. There were 52 women free of the previous fracture had a T-score diagnosis of
osteoporosis at baseline, and 12 of them had a new fracture during the follow-up. Table 1 compares
the baseline characteristics of women with and without any fracture during the follow-up. Women
who sustained a fracture were older (p < 0.001), had lower body mass index (BMI), higher prevalence
of prior fractures (p < 0.001), and more hip fractures in their family history (p = 0.002). T-score was
significantly lower in women with a fracture incidence (p < 0.0001). PGS was not significantly different
between women who sustained a fracture and women who did not (p = 0.81), yet was significantly
different between race groups (p < 0.0001).
Table 1. Baseline characteristics of 2417 women with and without any subsequent fracture during
19 years of follow-up.
Subjects with Any
Fracture Event (n = 289)

Subjects without Any
Fracture Event (n = 2128)

p Value

Age (year), mean (SD)

65.90 ± 7.33

62.38 ± 7.63

<0.0001

Weight (kg), mean (SD)

76.15 ± 15.59

77.56 ± 16.53

0.23

Height (cm), mean (SD)

161.61 ± 5.79

160.95 ± 6.01

0.12

Body mass index (kg/m2 ),
mean (SD)

29.16 ± 5.58

29.89 ± 5.97

0.08

Smoking, No. (%)
Never

166 ± 59.29

1191 ± 56.74

Past

100 ± 35.71

692 ± 32.397

Current

14 ± 5.00

216 ± 10.29

0.02

≥3 Alcoholic Drinks per Day
Yes

1 ± 0.35

18 ± 0.85

No

288 ± 99.65

2110 ± 99.15

0.72

Rheumatoid Arthritis, No. (%)
Yes
No

30 (10.38)

154 (7.24)

259 (89.62)

1974 (92.76)

0.06

Previous Fragility Fractures, No. (%)
Yes

114 (39.45)

528 (24.81)

No

175 (60.55)

1600 (75.19)

<0.0001

Familial History of Hip Fracture, No. (%)
Yes

40 (13.84)

177 (8.32)

No

249 (86.16)

1951 (91.68)

PGS, mean (SD)

2.27 ± 0.22

2.27 ± 0.23

0.002
0.81

T-score, mean (SD)

−1.36 ± 1.11

−0.72 ± 1.16

<0.0001

Follow up days (SD)

1967.19 ± 1457.08

5075.27 ± 2144.22

<0.0001

PGS: polygenic score calculated based on 63 BMD-related SNPs. Significant results are in boldface.

3.2. Performance of T-Score in Predicting MOF and Any Fracture
The T-score prediction versus the observed cumulative incidence of MOF and any fracture during
the 19-year follow-up period by PGS groups are shown in Figure 1A. The 19-year MOF incidence
derived from T-score significantly underestimated risk across all PGS groups. The most significant
underestimation by T-score was observed in women who had low PGS, in which the cumulative
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incidence of MOF was 3.83% versus observed 8.8%, with a corresponding predicted/observed ratio
(POR) of 0.43 (95% CI, 0.28–0.64), followed by the medium PGS group with a POR of 0.71 (95% CI,
0.56–0.90); and in the high PGS group, the POR was 0.72 (95% CI, 0.52–0.98). Similar results were
also observed when using any fracture as the outcome, the estimated incidence calculated by T-score
underestimated fracture risk in all PGS groups (Figure 1B).
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(B)
Figure 1. Observed versus predicted major osteoporotic fracture (A) and any fracture (B) probability
stratified by polygenic score group. The dotted line indicates a relative ratio of 1 (reference line); ratio
<1 indicates that T-score underestimates fracture risk.

The predicted versus the observed cumulative incidence of MOF and any fracture by racial groups
are shown in Figure 2. The T-score estimated incidence of MOF underestimated fracture risk in all
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racial groups except American Indians, with the statistically significant underestimation only observed
in African American and Caucasian women. In African American women, the predicted incidence
of MOF was 1.42% versus observed 2.73%, and the POR was 0.52 (95% CI 0.30–0.83). In Caucasian
women, the predicted incidence of MOF was 11.55%, as opposed to observed 18.38%, with the POR
being 0.63 (95% CI 0.50–0.78) (Figure 2A). Similarly in any fracture, significant underestimation of the
fracture incidence was observed in African American (POR: 0.19, 95% CI: 0.11–0.31), Hispanic (POR:
0.48, 95% CI: 0.33–0.67), and Caucasian women (POR: 0.47, 95% CI: 0.37–0.59) (Figure 2B).
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Figure 2. Observed versus predicted major osteoporotic fracture (A) and any fracture (B) probability
stratified by race. The dotted line indicates a relative ratio of 1 (reference line), ratio <1 indicates that
T-score underestimates fracture risk.
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3.3. PGS and the Fracture Outcome
In the Cox Proportional Hazard Model, after adjusting for baseline T-score classification, weighted
PGS calculated from 63 femoral neck BMD-related SNPs was not significantly associated with
subsequent MOF. Compared to the low PGS group, the probability of sustaining a MOF was 14% lower
for women with medium genetic risk (HR = 0.86, 95% CI 0.68–1.09) and 2% lower for women with
high genetic risk (HR = 0.98, 95% CI 0.75–1.28). Similar findings with the outcome of any fracture were
observed (Table 2). Results from the multinomial logistic regression indicated that the effect of PGS for
predicting hip fracture is not different from the effect of PGS for predicting non-hip fractures (p = 0.51)
(Table A1). Moreover, the predictive value of PGS in osteopenia participants and women with normal
BMD at baseline remained minimal (results not shown).
Table 2. Hazard Ratios (HR) with 95% Confidence Interval (CI) for Outcomes of Incidence Fracture
According to Polygenic Score Group, adjusted for T-score diagnosis, and race: Results from the Cox
Proportional Hazard Model.
Major Osteoporotic Fracture

Any Fracture

HR (95 % CI)

HR (95 % CI)

low

1 (reference)

1 (reference)

medium

0.86 (0.68–1.09)

0.81 (0.65–1.00)

0.98 (0.75–1.28)

0.89 (0.70–1.13)

Adjusted for T-score diagnosis

high

Significant results are in boldface.

3.4. Race/ethnicity and the Fracture Outcome
After controlling for baseline T-score, race remained a significant predictor of subsequent MOF
and any fracture. Compared to Caucasian women, African American women had a 59% lower hazard
of MOF (HR = 0.41, 95% CI 0.33–0.52) and 47% lower hazard of any fracture (HR = 0.43, 95% CI
0.32–0.88); American Indian women had a 41% lower hazard of MOF (HR = 0.59, 95% CI 0.35–0.99)
and 56% lower hazard of any fracture (HR = 0.44, 95% CI 0.36–0.54); Hispanic women had a 55% lower
risk of MOF (HR = 0.55, 95% CI 0.35–0.58) and 54% lower risk of any fracture (HR = 0.46, 95% CI
0.36–0.58). The potential impact of PGS on the estimated risk of MOF and any fractures across different
racial groups was also assessed. When adjusted for T-score and PGS group, the impact of race on
the estimated probabilities MOF and any fracture was slightly attenuated but remained statistically
significant. Similar results were observed when using any fractures as the outcome (Table 3). After
adjusting for other common risk factors of osteoporosis, only African American women remained to
have a significantly lower hazard of MOF (HR = 0.67, 95% CI 0.52–0.89) and any fracture (HR = 0.71,
95% CI 0.56–0.91), compared with Caucasian women (Table A2).
3.5. Sensitivity Analysis
We conducted a sensitivity analysis in which subjects who had previous fractures at baseline
were excluded (Tables A3 and A4). Results of the Cox Proportional Hazard Model remained the same
except that after adjustment for T-score diagnosis and PGS, the impact of race on the estimated risk of
MOF and any fractures attenuated slightly. Compare to Caucasian women, the adjusted hazard of
MOF was 43%, and 55% lower in African-American and Hispanic women, respectively. The hazard of
MOF was no longer significant between Caucasian and American Indian women. Similar results were
also observed when using any fracture as the outcome. The T-score classification perfomed slightly
different when comparing with observed 10-year cumulative incidence of fracture, with the 10-year
MOF incidence overestimated the risk of fracture in medium and high PGS groups (Figures A1–A4).
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Table 3. Hazard Ratios (HR) with 95% Confidence Interval (CI) for Outcomes of Incidence Fracture
According to Race Group, adjusted for T-score diagnosis, and Polygenic Score Groups: Results from
Cox Proportional Hazard Model.
Major Osteoporotic Fracture

Any Fracture

OR (95 % CI)

OR (95 % CI)

1 (reference)
0.59 (0.35–0.99)
0.41 (0.33–0.52)
0.45 (0.35–0.58)

1 (reference)
0.53 (0.32–0.88)
0.44 (0.36–0.54)
0.46 (0.36–0.58)

1 (reference)
0.56 (0.33–0.97)
0.41 (0.33–0.52)
0.44 (0.34–0.58)

1 (reference)
0.52 (0.31–0.87)
0.44 (0.35–0.54)
0.46 (0.36–0.59)

Adjusted for T-score diagnosis
Caucasian
American Indian
African American
Hispanic
Adjusted for T-score diagnosis + PGS
Caucasian
American Indian
African American
Hispanic

PGS: polygenic score calculated based on 63 bone mineral density-related SNPs. Significant results are in boldface.

4. Discussion
The present study provides compelling evidence that during the 19-year follow-up, the T-score
method underestimates the risk of MOF and any fracture in women 50–79 years old, across all racial
and PGS groups, especially in African Americans and women who have a low genetic risk. Moreover,
the prognostic performance of the T-score method estimated by false-positive rate and false-negative
rate using the cut-off value of −2.5 differed across race and PGS groups as well. Results from the
multivariate Cox proportional Models provided further evidence that the performance of the T-score
method in predicting osteoporotic fracture risks varies by race.
The BMD threshold defined by the WHO T-score method was found to be problematic. The
National Osteoporosis Risk Assessment Study found that 82% of 2259 women who reported fractures
had a T-score > −2.5 [22]. Similarly, in the Rotterdam Study of 7806 people, both 56% of women and
79% of men with non-vertebral fractures had a T-score of > −2.5 [23]. Other studies also demonstrated
that the majority of low-trauma fractures occur in individuals whose T-scores were above −2.5 [24,25],
which is consistent with the extremely high false-negative rates observed in the present study, especially
in African American and Hispanic women, as well as women who have a low genetic risk. However,
the percentage of being misclassified into a high-risk group without sustaining a fracture is highest
among Caucasian women when a T-score method is used to assess fracture risk. BMD is known
to be the single best predictor of fracture and the differences have been identified in the areal BMD
between ethnic and racial groups [26]. However, the observed cumulative incidence of fracture,
in terms of both MOF and any fracture, was significantly higher than the estimation derived from
the BMD-based T-score method in minorities. The results of multivariate Cox Proportional Hazard
Analysis further demonstrated that race is a significant predictor of MOF and any fracture independent
of the T-score classification. Although separate reference database was proposed for Africa Americans
and Hispanics [27], we did not use this ethnic-specific references in this study because whether the
T-score derived from the ethnic-specific database performs better or worse in osteoporosis diagnosis
remains unclear [28]. Nonetheless, our previous study suggested that a new classification method
of low BMD based on the race-specific lower limit of normal values may help mitigate some of the
T-score limitations in minority populations [29].
The present study found that T-score greatly underestimated the risk of fracture in women aged
50–79 years old, and the degree of underestimation by the T-score method in the low PGS group is
greater than in the high genetic risk groups in both outcomes of MOF and any fracture. However,
in the multivariate analysis, genetic profiling was demonstrated not to be a significant predictor of
MOF and any fracture, after T-score classification was adjusted for. Prior twin studies demonstrated

J. Clin. Med. 2020, 9, 499

11 of 17

that the heritable component of fracture is largely independent of BMD [30,31], whereas the reported
fracture-related genetic variants are also associated with BMD [32]. Due to the study power issue,
GWAS for dichotomous disease as a direct outcome has yielded relatively lower numbers of loci
discovered, and this is also the concern for osteoporotic fracture studies as well. Moreover, the
multifactorial nature of fracture is another issue that makes it challenging to identify the specific
genetic determinants that contribute to the risk of fractures. Therefore, the PGS constructed in the
present study may not sufficiently capture the BMD-independent genetic risk of fracture. With more
fracture-related genetic components being discovered, a more significant effect of PGS on fracture
risk prediction should be foreseen. Another possible reason for the minor effect of PGS on fracture
outcomes observed in the present study is that, similar to other age-related traits, the heritability of
fracture risk decreases with age [32]. Since the analytic sample consisted of older women, the effect
mediated through genetic influences on bone turnover, and bone geometry or non-skeletal factors such
as cognitive function, neuromuscular control, visual acuity, or other factors related to the risk of falling
might be more attributable to the predisposition of fracture [33].
Limitations of this study are acknowledged. First, the WHI data we used only included women
50–79 years old, so our findings may not apply to men or to women who are not in the age range
of this study. Second, genetic variants related to fracture risk independent of BMD remain mostly
undiscovered and likely most related genetic variants have not been included in the present study.
Therefore they had a limited impact on the T-score classification. Thirdly, concerning the allele
frequencies, osteoporotic fracture risk is associated with common and rare variants. Since all SNPs
used in the current study were based on a prior GWAS meta-analysis, which likely is able to discover
only common genetic variants, the BMD or fracture-related rare genetic determinants may not be
included. Finally, the sample size of minority subjects was very small in this study; the results may,
therefore, be underpowered.
5. Conclusions
To the best of our knowledge, this is the first study to assess T-score performance in the prediction
of MOF and any fractures in groups with different genetic profiling and of various races. Our
findings demonstrated that T-score performed differently in different races and PGS groups, and thus
the effect of race and genetic determinants in osteoporotic fracture prediction should be taken into
account beyond the T-score classification. Fully integrating genetic profiling and racial factors into the
existing fracture assessment model is very likely to improve the accuracy of osteoporosis diagnosis.
Thus, developing racial/ethnic-specific, individualized osteoporosis diagnosis methods will provide
more accurate fracture risk assessment and decrease false-positive rates and false-negative rates of
osteoporosis diagnosis. Further studies, especially these including men, a more extensive sample of
minorities, and more comprehensive fracture-associated genetic variants, are warranted.
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Appendix A
Table A1. Odds ratios (OR) with 95% Confidence Interval (CI) for Outcomes of Incidence Fracture
According to PGS Groups, adjusted for T-score diagnosis: Results from Multinomial Logistic Regression.
Type of Fracture

PGS Group

OR (95% CI)

Non-hip fracture

low

1 (reference)

med

0.85 (0.61–1.19)

high

0.82 (0.56–1.21)

low

1 (reference)

med

0.87 (0.47–1.61)

high

1.06 (0.54–2.09)

Hip fracture

Significant results are in boldface. Linear hypothesis testing results shows that the effect of PGS for predicting hip
fracture was not different from the effect of PGS for predicting non-hip fractures with a p-value of 0.51.

Table A2. Hazard Ratios (HR) with 95% Confidence Interval (CI) for Outcomes of Incidence Fracture
According to Race Group, adjusted for T-score diagnosis, Age, BMI, Previous Fracture, and PGS Groups:
Results from Cox Proportional Hazard Model.
Major Osteoporotic Fracture

Any Fracture

OR (95 % CI)

OR (95 % CI)

Caucasian

1 (reference)

1 (reference)

American Indian

1.21 (0.69–2.12)

0.92 (0.53–1.61)

African American

0.67 (0.52–0.88)

0.71 (0.56–0.91)

Hispanic

0.86 (0.64–1.16)

0.81 (0.61–1.07)

Caucasian

1 (reference)

1 (reference)

American Indian

1.15 (0.65–2.04)

0.90 (0.51–1.59)

African American

0.68 (0.52–0.89)

0.71 (0.56–0.91)

0.84 (0.61–1.15)

0.81 (0.60–1.08)

Adjusted for T-score diagnosis +age + BMI
+previous fracture

Adjusted for T-score diagnosis +age + BMI
+previous fracture + PGS

Hispanic

Significant results are in boldface.

Table A3. Hazard Ratios (HR) with 95% Confidence Interval (CI) for Outcomes of Incidence Fracture
According to PGS Group, adjusted for T-score diagnosis: Results from Cox Proportional Hazard Model,
Individuals with Previous Fractures were Excluded.
Major Osteoporotic Fracture

Any Fracture

HR (95 % CI)

HR (95 % CI)

low

1 (reference)

1 (reference)

medium

0.83 (0.65–1.06)

0.83 (0.68–1.00)

high

0.83 (0.68–1.02)

0.81 (0.65–1.02)

Adjusted for T-Score Diagnosis

Significant results are in boldface.

J. Clin. Med. 2020, 9, 499

13 of 17

Table A4. Hazard Ratios (HR) with 95% Confidence Interval (CI) for Outcomes of Incidence Fracture
According to Race Group, adjusted for T-score diagnosis: Results from Cox Proportional Hazard Model,
Individuals with Previous Fractures were Excluded.
Major Osteoporotic Fracture

Any Fracture

OR (95 % CI)

OR (95 % CI)

Caucasian

1 (reference)

1 (reference)

Adjusted for T-score diagnosis

American Indian

0.77 (0.49–1.21)

0.71 (0.46–1.11)

African American

0.57 (0.47–0.70)

0.58 (0.48–0.70)

Hispanic

0.45 (0.35–0.58)

0.45(0.35–0.57)

Caucasian

1 (reference)

1 (reference)

American Indian

0.77 (0.48–1.23)

0.71 (0.45–1.12)

African American

0.57 (0.47–0.70)

0.58 (0.48–0.70)

0.45 (0.35–0.59)

0.46 (0.36–0.58)

Adjusted for T-score diagnosis +
weighted PGS

Hispanic

Significant results are in boldface.
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